BDRX
NASDAQBiodexa Pharmaceuticals plc American Depositary Shs
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$3.12-0.05 (-1.58%)
06:45 PM07:00 PM
News · 26 weeks57-100%
2025-12-142026-06-07
Mix2890d
- SEC Filings15(54%)
- Insider6(21%)
- Other6(21%)
- Leadership1(4%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biodexa Pharmaceuticals plc American Depositary ShsSCHEDULE 13G/A - Biodexa Pharmaceuticals Plc (0001643918) (Subject)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRBiodexa issues letter to ShareholdersMay 14, 2026 Biodexa issues letter to Shareholders Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers has today issued the following letter to shareholders explaining the proposals to reorganize the company's share capital at the forthcoming Annual General Meeting. For holders of ADSs, the proposals will impact neither the number of ADSs held nor percentage ownership nor shareholder's rights. "Dear Shareholder, Annual General Meeting Proposals to Reorganize Share Capital Without Affecting Shareholder's Rights or Number of ADSs Outstanding With this lette
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 424B3 filed by Biodexa Pharmaceuticals plc American Depositary Shs424B3 - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRBiodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial SuppliesApril 2, 2026 Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, is pleased to announce that it has partnered with Syngene International Ltd (BSE: 539268, NSE: SYNGENE) ("Syngene") for the manufacture of both MTX240 active pharmaceutical ingredient and dosage form. Commenting, Dan Palmer, Vice President, Technology at Biodexa said "We are delighted to be partnering with Syngene for the s
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form EFFECT filed by Biodexa Pharmaceuticals plc American Depositary ShsEFFECT - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 20-F filed by Biodexa Pharmaceuticals plc American Depositary Shs20-F - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRPreliminary Results for the Year Ended 31 December 2025March 27, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company" or, together with its subsidiaries, the "Group") Preliminary Results for the Year Ended 31 December 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers, announces its audited preliminary results for the year ended 31 December 2025. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO Fiona Sharp, CFOTel: +44 (0)29 2048 0180www.biodexapharma.com About Biodexa The Company's lead development programs include eRapa, under development for Familial Adenoma
- PRBiodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma GroupMarch 23, 2026 Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers is pleased to announce that it has entered into a strategic partnership with Tanner Pharma Group to make eRapa available for Familial Adenomatous Polyposis (FAP) patients via an Early Access Program and Named Patient prescribing. This initiative gives clinicians who treat FAP patients the opportunity to prescribe this investigational medicine outside of a clinical trial
- INSIDERSEC Form 3 filed by new insider Parker Stephen Barry3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)
- SECSEC Form 6-K filed by Biodexa Pharmaceuticals plc American Depositary Shs6-K - Biodexa Pharmaceuticals Plc (0001643918) (Filer)
- PRADR Ratio ChangeMarch 18, 2026 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") ADR Ratio Change Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts ("ADR") from one (1) ADR representing one hundred thousand (100,000) ordinary shares, to the new ratio of one (1) ADR representing five hundred thousand (500,000) ordinary shares (the "Ratio Change"). The effective date of the Ratio Change is expected to be on or about April 6, 2026. Pursuant to the Ratio Change, ADR holders will be required on a
- INSIDERSEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)
- INSIDERSEC Form 3 filed by Biodexa Pharmaceuticals plc American Depositary Shs3 - Biodexa Pharmaceuticals Plc (0001643918) (Issuer)
BDRX FAQ
5 questionsWhere does BDRX stock trade?
Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) is listed on NASDAQ.What sector and industry is BDRX in?
Biodexa Pharmaceuticals plc American Depositary Shs operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BDRX?
Biodexa Pharmaceuticals plc American Depositary Shs has had 1 recent analyst action on file. The most recent action was from Ladenburg Thalmann: Buy with a $800.00 price target on 2024-02-08. Recent price targets cluster around $800.00.What companies are similar to BDRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BDRX side-by-side with any of them on Quantisnow.How can I track BDRX on Quantisnow?
Quantisnow aggregates Biodexa Pharmaceuticals plc American Depositary Shs's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDRX to receive live email and push alerts on every new disclosure.